Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Endocrine and neuroendocrine tumours

3117 - Different RNA expression profile defines prognosis in grade 1/2 neuroendocrine neoplasms of small intestine origin. The GETNE-NETSEQ study

Date

10 Sep 2017

Session

Endocrine and neuroendocrine tumours

Presenters

Jaume Capdevila

Citation

Annals of Oncology (2017) 28 (suppl_5): v142-v157. 10.1093/annonc/mdx368

Authors

J. Capdevila1, F. Mancuso2, S. Landolfi3, F. Salva4, C. Miguel5, P. Jiménez-Fonseca6, R. Garcia-Carbonero7, C. López López8, A. Casteras9, T. Sauri Nadal1, P. Nuciforo10, A. Vivancos2, I. Matos1

Author affiliations

  • 1 Medical Oncology, Vall d'Hebron University Hospital. Vall Hebron Institute of Oncology (VHIO), 08035 - Barcelona/ES
  • 2 Cancer Genomics Group, Vall d´Hebron Institute of Oncology, 08035 - Barcelona/ES
  • 3 Anatomic Pathology Department, Vall d'Hebron Hospital, 08035 - Barcelona/ES
  • 4 Medical Oncology, Mataró Hospital, Barcelona/ES
  • 5 Pathology, H. U. Central de Asturias, Oviedo/ES
  • 6 Medical Oncology, H. U. Central de Asturias, 33011 - Oviedo/ES
  • 7 Medical Oncology Department, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 8 Oncology, Hospital Universitario Marqués de Valdecilla, Santander/ES
  • 9 Endocrinology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 10 Molecular Oncology Group, Vall d´Hebron Institute of Oncology, 08035 - Barcelona/ES
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3117

Background

Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors with different prognosis. Clinical and pathological factors are used to predict outcome but there are some patients that have a poor outcome even with good classical prognostic factors. We aimed to define a different RNA expression profile (EP) that could detect patients with worse prognosis and identify possible targetable new pathways.

Methods

We identified 48 paraffin-embedded archival tumor material of patients with metastatic grade 1/2 NENs of small intestine origin for RNAseq. We generated on average 66 million paired-end reads for each sample on HiSeq2500 (Illumina). RNAseq reads were mapped against the human reference genome (hg19) with Tophat (v2.0.14) and quantified using Cufflinks tools suite (v.2.2.1). 41 samples had sufficient quality to be included in the analysis. We used multivariate Cox proportional models to study the association between EP, clinical variables (gender, age, location of metastases, hormone production and Ki67 index) and overall survival (OS). We defined as poor outcome those patients that died within the first 3 years of the diagnosis of advanced disease.

Results

9348 transcripts were quantified. A gene signature of 329 transcripts was defined by a two-way statistical analysis between poor and long term survivors. A pathway enrichment analysis of these genes showed a deregulation in the poor prognosis group on the PI3KCA-Akt-mTOR and the Toll-like receptor signaling pathways. The hazard ratio (HR) for mOS defined by EP comparing poor and long term survivor groups was 0.33, 95% CI 0.1-1.1, p = 0.081 in the univariate analysis and HR of 0.05, 95% CI 0.005-0.51, p = 0.011 in the multivariate analysis.

Conclusions

We identified statistically different RNA-clusters and different deregulated pathways for those patients with advanced NENs of small intestine origin with poor prognosis. To our knowledge, this is the first time that Toll-like pathway is involved in the pathogenesis of NENs. These results are relevant as they may help improve the prognosis stratification of patients and involve novel targetable pathways of great clinical potential.

Clinical trial identification

Legal entity responsible for the study

Vall d’Hebron Institute of Oncology

Funding

Spanish Task Force for Neuroendocrine and Endocrine Tumors (GETNE)

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.